

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Tocilizumab for treating systemic sclerosis ID1396

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche (tocilizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arthritis Research UK • Bladder and Bowel Community • British Lung Foundation • Changing Faces • Genetic Alliance UK • Kidney Care UK • Let's Face it • Muslim Council of Britain • Scleroderma and Raynaud's Association • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • Association of Renal Technologists • Association of Respiratory Nurse Specialists • Association of Respiratory Technology and Physiology • British Association of Dermatologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Dermatological Nursing Group • British Geriatrics Society • British Renal Society • British Skin Foundation • British Society for Rheumatology • British Society of Gastroenterology • British Thoracic Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (methotrexate, mycophenolate) • Actavis (mycophenolate) • Baxter Healthcare (cyclophosphamide) • Generics UK T/A Mylan (mycophenolate) • Hameln Pharmaceuticals (methotrexate) • Hospira UK (methotrexate) • Medac GmbH (methotrexate) • Napp Pharmaceuticals (rituximab) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals UK (mycophenolate)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Primary Care Dermatology Society • Primary Care Respiratory Society UK • Primary Care Rheumatology Society • Primary Care Society for Gastroenterology • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Vascular Nurses • Tissue Viability Society • UK Clinical Pharmacy Association • UK Renal Pharmacy Group • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Dudley CCG • NHS England • NHS Kingston CCG • Welsh Government 	<ul style="list-style-type: none"> • Orion Pharm UK (methotrexate) • Pfizer (methotrexate) • Roche Products (mycophenolate, rituximab) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (cyclophosphamide, methotrexate, mycophenolate, rituximab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • British Epidermo-Epidemiology Society • British Society for Dermatological Surgery • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Kidney and Transplant Group • Cochrane Musculoskeletal Group • Cochrane Skin Group • Cochrane Vascular • Cochrane Wound Group • CORE (Digestive Disorders Foundation) • MRC Clinical Trials Unit • National Institute for Health Research • Skin Treatment & Research Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.